This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ASCO® 2021
Presentations
Enfortumab Vedotin | Urothelial Carcinoma | Abstract 4528
Study EV-103: Update on Durability Results and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in First Line Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Enfortumab Vedotin | Urothelial Cancer | Abstract 4524
Enfortumab Vedotin in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer Who Received Prior PD-1/PD-L1 Inhibitors: An Updated Analysis of EV-201 Cohort 2
Enfortumab Vedotin | Urothelial Carcinoma | Abstract 4539
Quality of Life, Functioning, and Symptoms in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma From EV-301: A Randomized Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy
Enfortumab Vedotin | Bladder Cancer | Abstract TPS4587
KEYNOTE-B15/EV-304: Randomized Phase 3 Study of Perioperative Enfortumab Vedotin Plus Pembrolizumab Versus Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC)